QCG
CTKB icon

Quadrant Capital Group’s Cytek Biosciences CTKB Stock Holding History

Quadrant Capital Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,594
Closed -$6.39K – 1640
2025
Q1 		$6.39K Buy
1,594
+1,495
+1,510% +$7.75K ﹤0.01% 2308
2024
Q4 		$643 Hold
99
– – ﹤0.01% 2629
2024
Q3 		$549 Buy
+99
New +$561 ﹤0.01% 2666

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Quadrant Capital Group's CTKB Position: Q2 2025 in Review

Quadrant Capital Group sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 1,594 shares — an estimated $6.39K sold.

Quadrant Capital Group first reported a position in CTKB in Q3 2024 and held it in 3 quarters. The position peaked at $6.39K in Q1 2025. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

  • Quadrant Capital Group reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 1,594 Cytek Biosciences shares in Q2 2025, an estimated $6.39K.
  • Quadrant Capital Group first reported a position in Cytek Biosciences in Q3 2024 and held it in 3 quarters.
  • Quadrant Capital Group's Cytek Biosciences position peaked at $6.39K in Q1 2025.
  • 158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.